The deleted in liver cancer 1 
. Rho-GTPase activity is frequently dysregulated in human cancers and may contribute to the growth and invasiveness of tumour cells [4, 5] . The human genome encodes [20] [21] [22] Rho proteins, of which the best characterized are RhoA, Rac1 and Cdc42 [6, 7] .
In common with other Ras-like GTPases, Rho proteins act as molecular switches that undergo a nucleotide-regulated conformational change. In the GTP-bound state they transmit signals by activating downstream effector molecules, such as protein and lipid kinases, phospholipases and regulators of cytoskeletal organization [1, 3]. The Rho GTP-GDP cycle is controlled by two classes of regulatory proteins; guanine nucleotide exchange factors (GEFs)
promote the exchange of bound GDP for GTP to generate the active state, and GTPase activating proteins (GAPs) stimulate GTP hydrolysis to reconstitute the inactive state [8] .
In human beings, the ~70 RhoGEFs and ~80 RhoGAPs are structurally diverse multi-domain proteins, and their activities are regulated and targeted by interactions with other molecules [9] [10] [11] [12] . A number of RhoGEFs are activated in response to stimulation of cell surface receptors, and several GEFs have been localized to complexes organized by scaffolding proteins that include downstream Rho effectors, which would increase the efficiency and specificity of Rho signalling [13, 14] [12, 15] 
. While fewer details are known about RhoGAP signalling pathways, their importance in normal cellular homeostasis is evidenced by the association of several human disorders with mutations in RhoGAP genes and by the abnormal phenotypes generated by targeted inactivation of mouse RhoGAP genes

. One RhoGAP that is rapidly gaining recognition for its role as a tumour suppressor and a regulator of cell proliferation and cytoskeletal organization is DLC-1 (deleted in liver cancer 1). In this review we summarize the current state of knowledge of DLC-1 and its relatives.
The deleted in liver cancer family of RhoGAP domain proteins
The DLC-1 gene was identified by Yuan and colleagues as a genomic DNA segment under-represented in a human hepatocellular carcinoma (HCC) specimen, using representational difference analysis, a PCR-based subtractive hybridization technique [16] . The DLC-1 locus was mapped to the human chromosome 8p22 region frequently lost in HCC and other cancers (Fig. 1A) , and it was named 'deleted in liver cancer' when found to be deleted in primary HCC and HCC cell lines [16] . Sequencing of the DLC-1 cDNA showed that it was the human orthologue of the rat p122RhoGAP protein, which had been cloned by Homma and Emori when screening a gt11 expression library with anti-serum against phospholipase C ␦1 (PLC ␦1) [17] . The predicted amino acid sequence of p122RhoGAP/DLC-1 contains a RhoGAP domain, a conserved region of around 200 amino acids responsible for the catalytic activity of RhoGAPs [10] . [18] .
Further analysis of the DLC-1 polypeptide sequence revealed the presence of two additional conserved elements, an N-terminal sterile alpha motif (SAM) domain and a Cterminal steroidogenic acute regulatory protein (StAR)-related lipid-transfer (START) domain
DLC-1 was later recognized as the founding member of a family of proteins that shares the SAM-RhoGAP-START domain organization, which now includes DLC-2 (also known as STARD13, for START domain-containing protein 13) [19, 20] and DLC-3 (also known as KIAA0189 and STARD8) [21, 22] (Fig. 2) . The genes encoding the three human DLC proteins appear to be paralogues that arose through duplication of chromosomal segments [22] [17] and 92% identical to the mouse protein [24, 25] [24, 25] .
Several variant transcripts are associated with the DLC1 locus (Table 1 and Fig. 3A) [19, 20] . The full-length DLC-2 cDNA is Ϸ6 kb, and on Northern blots an additional 4 kb transcript was detected in some tissues [19] [16, 24, 30] [24] . The distribution of the DLC-2 and DLC-3 mRNAs appears to overlap with that of DLC-1 in many adult tissues [19, 21, 22] 
org). Both of the predicted gene products lack the SAM domain; however, further characterization of the 5' ends of the gei-1 transcripts will be needed to confirm the absence of a SAM domain. The 842-aa protein is slightly more similar to DLC-2 (33% identity) than to DLC-1 or DLC-3 (30% identity).
Expression of DLC family proteins
DLC-1 mRNA is widely expressed in human and mouse tissues, as shown by Northern blot hybridization
Features of DLC family protein domains SAM domain
The N-terminus of the DLC-1 polypeptide contains a SAM domain (aa , an Ϸ70 amino acid motif that occurs in more than 200 human proteins, including transcription factors and signalling proteins [35] . Most [19, [39] [40] [41] . Human DLC-1 and DLC-2 have also been reported to increase the hydrolysis of Cdc42-GTP in vitro, although less efficiently than that of RhoA-GTP, and both had little effect on the GTPase activity of Rac1 [22, 40] .
START domain
The START domain at the C-terminus of DLC-1 (aa 878-1081) is a domain first identified in several proteins with a role in lipid transport or lipid metabolism, and subsequently START domains have been found in 15
human proteins [18, 42] . The 3D structures obtained for several START domains show that they exist as a hydrophobic tunnel formed by a curved, 9-stranded ␤ sheet gripped by N-terminal and C-terminal ␣ helices [42] . Different lipid-binding modules are found in other RhoGAP proteins, such as the Sec14 domain in Cdc42GAP and C1 domain in ␤2-chimaerin, and they are thought to regulate the subcellular localization of the protein and/or its GAP activity [10, 43] . However, it has been suggested that START domains may not be involved in membrane targeting due to buried nature of lipid-binding region [44] . Determination of the identity of the ligand(s) for the START domains of the DLC family proteins will be essential for understanding the function of this region.
Serine-rich, unstructured middle region
The region between the SAM and RhoGAP domains of DLC-1 (aa (Fig. 4) [47, 48] -638 ) of human DLC-1 is shown, and residues that were found to be phosphorylated in the mouse [51] and rat [49, 50] [39, 55, 56] (Fig 1D and E) . Using overlapping deletion mutants, the ability of DLC-1 to disrupt the cytoskeleton was shown to require the presence of the RhoGAP domain, and point mutations that abolished GAP activity reduced this inhibitory effect [39, 55, 56] [41, 60] . Binding of DLC-1 to the PTB domains of tensin1 and tensin2 was also detected [41, 59] , and DLC-1 competed with integrin ␤3 for binding to the tensin1 PTB domain [41] . Tensin and DLC-1 co-localize (Fig. 5 [41, 59, 60] . [62] . Endogenous DLC-1 was found to sediment with caveolin-1 in low-density cholesterol-rich membrane fractions [63] , and both endogenous and myc-tagged DLC-1 were co-immunoprecipitated with caveolin-1 [59, 63] . Since multiple functions have been proposed for caveolae [62, 64] , and caveolin-1 has been found in membrane subdomains other than caveolae, including focal adhesions [64, 65] , the physiological significance of the interaction between DLC-1 and caveolin-1 requires further investigation. [39] . Whether DLC-2 and
. Instead, this domain has several features in common with a class of proteins that have been termed intrinsically unstructured (or disordered) proteins
), and the localization of ectopically expressed DLC-1 to focal adhesion-like structures was dependent on the co-expression of tensin proteins
Interaction of DLC-1 with caveolin-1
Caveolin-1 is a 22 kD protein that is an essential component of caveolae, plasma membrane domains that appear as flask-shaped invaginations at the cell surface and are enriched in cholesterol and sphingolipids
DLC-1 and phosphoinositide signalling
DLC-3 also interact with PLC-␦1 has not been determined. In addition to serving as a precursor for other lipid second messengers, PIP2 also has an important role in regulating cytoskeleton assembly by inducing conformational changes in actin-binding proteins, such as vinculin and talin [67]. Thus DLC-1 could influence cytoskeletal dynamics by altering local PIP2 levels as well as by regulating Rho
GTPase activity.
Biological activities of DLC-2 and DLC-3
Consistent with its similarity to DLC-1, over-expression of DLC-2 has been found to induce cell rounding and disrupt actin filaments in liver and breast can-
cer cells [20, 27] , and this effect was eliminated by mutation of critical residues in the RhoGAP domain [27] . When recombinant DLC-2 was expressed at lower levels to reduce cytotoxicity, the protein was found to co-localize with mitochondrial markers, using immunofluorescence and cell fractionation [68] . DLC-2 was also detected in structures that resembled lipid droplets, and targeting to mitochondria and lipid droplets was mapped to the START domain [68] . Recombinant DLC-2 was found to form homodimers in solution, and residues 120-672 were responsible for self-association [36] . [41] . [69] .
It will be of interest to determine whether dimerization is a property of the other DLC family proteins. Studies on the biological functions of DLC-3 have just begun, but the amino acid sequence contains a segment similar to the DLC-1 tensin-binding site (STYDNL, aa 353-358) and full-length DLC-3␣ was shown to bind the SH2 and PTB domains of tensin1
Genetic analysis of DLC-1 function Mouse DLC-1 gene knockout
Evidence that DLC-1 has a crucial role in cytoskeletal organization and morphogenesis in vivo has come from the discovery that null mutations in the gene result in embryonic lethality in mice and flies. We used gene targeting to disrupt the mouse DLC-1
Fig. 5 Co-localization of DLC-1 and tensin. Confocal photomicrographs showing endogenous tensin (red, A) and transfected GFP-DLC1 fusion protein (green, B) in human fibroblasts. The merged image (C) shows co-localization of tensin and DLC-1 in focal adhesions
RhoGAP88C in Drosophila
The Drosophila DLC-1 orthologue RhoGAP88C was found to be essential for viability in a study using RNA interference to inactivate Drosophila RhoGAP genes [70] . [28] . [71, 72] [53] .
Two recent studies indicated that cv-c is required for the cell shape changes that take place during epithelial invagination in Drosophila spiracle and trachea morphogenesis. The apical constriction of the invaginating cells of the trachea and the posterior spiracle depended on the activation of Rho1 at the apical membrane and the consequent apical accumulation of F-actin and myosin II [71, 72]. In cv-c mutants, the invagination defects in tracheal and spiracle cells were associated with the abnormal subcellular distribution of F-actin and myosin II
The DLC family proteins in cancer Decreased expression of DLC-1 in human cancers
Rho GTPases are involved in the regulation of cellular processes, such as proliferation, motility and apoptosis that are typically altered during oncogenesis [74] . Rho GTPase activity is increased in a variety of human cancers, but this has not been associated with the occurrence of activating mutations in Rho protein genes, in contrast with Ras [5, 75] [16, 40, 76] , breast [77] [78] [79] colon [79] , ovarian [79, 80] , uterine [79] , gastric [33] , lung [79, [81] [82] [83] , pancreatic [84] , prostate [85] , renal [79] and nasopharyngeal tumours [86] . Reduced mRNA levels have also been found in non-malignant conditions, such as uterine fibroids [87] and benign prostatic hyperplasia [85] . There had been little data on the relative abundance of the DLC-1 protein in normal and neoplastic tissues, but recently decreased DLC-1 protein levels were reported in prostate tumour samples compared to normal prostate tissue [85] .
Deletions of DLC1 in tumours
The 8p22 region-containing DLC1 is commonly under-represented in a variety of solid tumours and haematological malignancies [88] , and deletions at the DLC1 locus were detected in HCC cell lines and primary HCC using Southern blot hybridization and loss of heterozygosity (LOH) analysis [16, 40, 76] . Subsequently DLC1 copy number losses were found in other common human cancers, including breast [77, 89] , lung [81] , nasopharyngeal [86] and prostate cancer [85] . Although the 8p21-22 regions does not correspond to a fragile site (FS), its propensity for deletion is similar to that of the most unstable and vulnerable FSs [90, 91] . The proximity of DLC1 to a break in the mouse/human synteny [24] could predispose it to deletions, since these evolutionary breakpoints often coincide with regions of instability in tumours [92] .
Epigenetic inactivation of DLC-1 expression
Epigenetic mechanisms also lead to silencing of tumour suppressor genes, and hypermethylation of cytosine bases within CpG dinucleotides in GC-rich promoter regions is the best characterized chromatin modification associated with transcriptional repression in human malignancies [93] . The first evidence implicating aberrant promoter methylation in the down-regulation of the DLC-1 gene was obtained by screening several cell lines derived from HCC, breast, colon and prostate tumours [32] . Subsequent analyses showed that promoter methylation is the principal mechanism responsible for inactivation of the DLC-1 gene in a number of solid tumours ( Table 2) . Hypermethylation of the DLC-1 promoter may be an early event in the development of prostate neoplasms, as it was also observed in a majority of benign prostatic hyperplasia cases [85] . Aberrant DLC1 methylation has been detected in several haematological malignancies (Table 3) , which is of interest, since DLC-1 mRNA levels are low in normal peripheral blood leucocytes but can be detected in lymph node, thymus and spleen [22, 97] [32, 33, 40, 85, [94] [95] [96] 98] .
Alterations in histone modifications also occur in cancer and may contribute to silencing of DLC-1. Transcriptional repression has been linked with histone hypoacetylation, which is promoted by the recruitment of histone deacetylases to chromatin [99] . DLC-1 expression was increased after treatment with the histone deacetylase inhibitor trichostatin A (TSA) in several human gastric cancer [33] , prostate cancer [85] , multiple myeloma [96] and leukaemia [98] cell lines. In some cell lines DLC-1 was not induced by TSA unless the cells were co-treated with 5-aza-2'-deoxycytidine [33, 97, 98] [101] . Recently DLC1 and several other genes silenced by methylation in cancer were found to be targets of PcG proteins in human embryonic fibroblasts [102] and human embryonic stem cells [103] . PcG binding to [102, 104] .
DLC-1 sequence variants in human cancers
Mutational analysis of the DLC-1 gene in tumour DNA samples revealed that somatic mutations in the coding region are uncommon in HCC [76, 105] and colorectal [30] , ovarian [30] , brain [106] , head and neck [107] and prostate cancers [108] . [109] , but a mutation screening and association study did not reveal significant differences in the DLC1 SNP frequencies in prostate cancer cases and controls [108] . However, in a large-scale genomic screen, DLC1 was identified as a highly significant breast cancer susceptibility gene [110, 111] . [55] [56] [57] 76] and in breast [77, 89] , lung [41, 81, 83] , nasopharyngeal [34] , oesophageal [34] and epithelial ovarian cancer cells [112] (Fig. 1B) . DLC-1-mediated inhibition of HCC and ovarian cancer cell proliferation was associated with the induction of apoptosis (Fig. 1G) , marked by the cleavage of procaspase-3 [57, 112] . DLC-1 expression reduced anchorage-independent growth of HCC [55] , ovarian cancer [112] and lung cancer [41] [89] and non-small cell lung cancer cells [81] , and the size of tumours was reduced in HCC cells [55, 57] (Fig. 1F) [98] metastatic subclones compared to non-metastatic ones [114] . In assays using cultured cells, re-expression of DLC-1 inhibited the motility and invasiveness of HCC [55] [56] [57] (Fig. 1C) , breast cancer [115] , ovarian cancer [112] and lung cancer cell lines [41] . Both the RhoGAP and tensin-binding activities have been implicated in the inhibition of migration [41] . [120, 121] . [129] .
DLC-1 suppresses tumour cell growth
Regulation of DLC-1 by anti-oncogenic factors
Evidence for roles of DLC-2 and DLC-3 in neoplasia
In addition to their structural and functional similarities with DLC-1, the other two human DLC family genes may also be involved in oncogenesis. The STARD13/DLC2 locus at chromosome 13q13 is another frequent target of genomic DNA deletions in several human cancers [88] . LOH at the 13q13 locus and under-expression of DLC-2 were observed in primary HCC tissues [19] . Down-regulation of DLC-2 mRNA was also detected in a significant fraction of primary lung, ovary, kidney, breast and uterine tumours [79] . The GAP domain of DLC-2 was able to suppress Ras signalling and inhibit the transformation of NIH3T3 cells when co-transfected with oncogenic Ras [19] . DLC-2 over-expression was found to inhibit the growth of MCF-7 breast cancer cells [20] . Transfection of the DLC-2␥ isoform into the HepG2 cell line decreased proliferation, RhoA activity, motility and the ability to form colonies in soft agar [27] . The STARD8/DLC3 locus on chromosome Xq13 is near a site of LOH in ovarian cancers [130] , but this region has not been reported to be frequently deleted in other cancer types [131] . Reduced DLC-3 mRNA levels were observed in a majority of human prostate, kidney, lung, breast, uterine and ovarian cancer tissues analysed [22] . Over-expression of DLC-3 inhibited the proliferation, colony forming ability, and anchorage-independent growth of human breast and prostate cancer cell lines [22] . In a largescale analysis of mutations in human breast and colon cancers, two missense mutations in STARD8/DLC3 were found in breast tumours [132] . Whether these alterations, both located in the SR region (Gly268Ser and Glu322Lys, in the DLC-3␣ amino acid sequence), have an effect on DLC-3 activity remains to be determined. 
Conclusions and future directions
